Literature DB >> 11535108

The pharmacogenetics of analgesia: toward a genetically-based approach to pain management.

C M Flores1, J S Mogil.   

Abstract

Interindividual differences in the experience of pain have been appreciated clinically for over a century. More recently, there has been a growing body of evidence demonstrating differences in analgesic response to various pharmacotherapies, although the source of this variability largely remains to be explained. To this end, basic science research is beginning to identify the allelic variants that underlie such antinociceptive variability using a multiplicity of animal models, and powerful genetic approaches are being exploited to accelerate this process. Although the vast majority of these studies have focused on the pharmacogenetics of opioids, owing to their prominent status as analgesics, the number of pharmacotherapies evincing genetically-based variability is rapidly expanding. In addition, analogous studies have been undertaken in humans, as a small but growing number of clinical trials have begun to evaluate prospectively the existence, if oftentimes not the origin, of interindividual differences in analgesic drug response. Importantly, with a few notable exceptions, such efforts have primarily identified differences in analgesic efficacy and/or potency between male and female human subjects. Looking toward the future development of one or more widely utilised, pharmacogenetic screens that would lead to modifications in treatment planning, at least with respect to the pharmacologic management of pain, this review will document the breadth of genetically-based variability in drug-mediated antinociception in animals. Specific examples in which the gene or genes underlying such variability have been postulated or identified will be given, while highlighting the effect of sex and its interactions with other genetic backgrounds. Finally, we will summarise and evaluate the literature on pharmacogenetic differences in human analgesic drug response, for which the influence of sex has served as one of the better studied and heuristically insightful examples.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535108     DOI: 10.1517/14622416.2.3.177

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  8 in total

Review 1.  MicroRNAs in opioid pharmacology.

Authors:  Cheol Kyu Hwang; Yadav Wagley; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-09       Impact factor: 4.147

2.  Persistent pain model reveals sex difference in morphine potency.

Authors:  Xiaoya Wang; Richard J Traub; Anne Z Murphy
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-02-23       Impact factor: 3.619

Review 3.  Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions.

Authors:  Roland Staud
Journal:  Expert Rev Neurother       Date:  2012-05       Impact factor: 4.618

4.  Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.

Authors:  Cielito C Reyes-Gibby; Sanjay Shete; Trude Rakvåg; Samrat V Bhat; Frank Skorpen; Eduardo Bruera; Stein Kaasa; Pål Klepstad
Journal:  Pain       Date:  2006-12-06       Impact factor: 6.961

Review 5.  Translational pain research: achievements and challenges.

Authors:  Jianren Mao
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

Review 6.  Epigenetics: a promising paradigm for better understanding and managing pain.

Authors:  Seungmae Seo; Adrienne Grzenda; Gwen Lomberk; Xiao-Ming Ou; Ricardo A Cruciani; Raul Urrutia
Journal:  J Pain       Date:  2013-04-19       Impact factor: 5.820

Review 7.  Clinical use of opioids for cancer pain.

Authors:  Dermot R Fitzgibbon
Journal:  Curr Pain Headache Rep       Date:  2007-08

8.  CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.

Authors:  Concetta Dagostino; Massimo Allegri; Valerio Napolioni; Simona D'Agnelli; Elena Bignami; Antonio Mutti; Ron Hn van Schaik
Journal:  Pharmgenomics Pers Med       Date:  2018-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.